Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fucosylated Tregs for GVHD Prevention
NCT02423915Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Oct 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UCB-Tregs (fucosylated) in graft-versus-host disease (GVHD) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Severe Infusional Toxicity at 100 days and Safety of Administering Fucosylated Umbilical Cord Blood Regulatory T cells at 100 days. Started Jul 2015; status: completed.
02
Drugs
UCB-Tregs (fucosylated)
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02423915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423915.